US 12,168,037 B2
Intracellular IL-1 alpha peptide methods and compositions
Jargalsaikhan Dagvadorj, Los Angeles, CA (US); Moshe Arditi, Encino, CA (US); Gantsetseg Tumurkhuu, Los Angeles, CA (US); and Janet Markman, Encino, CA (US)
Assigned to Cedars-Sinai Medical Center, Los Angeles, CA (US)
Appl. No. 16/963,421
Filed by CEDARS-SINAI MEDICAL CENTER, Los Angeles, CA (US)
PCT Filed Jan. 23, 2019, PCT No. PCT/US2019/014732
§ 371(c)(1), (2) Date Jul. 20, 2020,
PCT Pub. No. WO2019/147658, PCT Pub. Date Aug. 1, 2019.
Claims priority of provisional application 62/621,461, filed on Jan. 24, 2018.
Prior Publication US 2021/0060131 A1, Mar. 4, 2021
Int. Cl. A61K 38/20 (2006.01); A61K 38/08 (2019.01); A61P 35/00 (2006.01); A61P 35/04 (2006.01); C07K 14/545 (2006.01)
CPC A61K 38/2006 (2013.01) [A61P 35/00 (2018.01); A61P 35/04 (2018.01); C07K 14/545 (2013.01); A61K 38/08 (2013.01)] 7 Claims
 
1. A method for reducing and/or reducing the likelihood of cancer metastasis in a subject in need thereof, comprising:
administering a therapeutically effective dosage of a pro-interleukin-1α (pro-IL-1α) peptide mimic to the subject to reduce and/or reduce the likelihood of the cancer metastasis,
wherein the pro-IL-1α peptide mimic consists of the amino acid sequence of SEQ ID NO: 1, or
wherein the pro-IL-1α peptide mimic consists of the amino acid sequence of SEQ ID NO: 1 with 1, 2, or 3 amino acid substitutions, deletions or additions.